Views
15
Downloands
3
Tümör nekroz faktörü inhibitörü (TNFi) tedavileri günümüzde birçok romatizmal hastalıkta en önemli tedavi basamaklarından birini oluşturmaktadır. Bununla birlikte, bu ajanların kullanımının birçok paradoksal otoimmün hastalığın gelişimi ile ilişkili olduğu gösterilmiştir. Bu vaka sunumunda etanersept tedavisi altında paradoksal sarkoidoz gelişen hastayı güncel literatür eşliğinde tartışmayı amaçladık. Psöriatik artrit (PsA) tanısı ile 3 yıldır etanercept (50 mg/hafta subkutan) kullanan 40 yaşındaki erkek hastanın akciğer görüntülemesinde mediastinal lenfadenopati ve her iki akciğer alanında santral yerleşimli nodüller saptandı. Lenf bezi biopsi sonucu non kazeifiye granülomatöz inflamasyon saptandı. Asemptomatik paradoksal sarkoidoz olarak kabul edilen hastanın etanersept tedavisi sonlandırıldı. Hastanın 6. ay takibinde PsA klinik aktivite skorlarında artış saptandı. Bu nedenle hastaya İnterlökin 17A inhibitörü (anti-IL17A) olan sekükinumab tedavisi başlandı. Hastanın birinci yıl takibinde mediastinal lenf nodlarında tama yakın regresyon izlendi. TNFi tedavisi sırasında paradoksal sarkoidoz gelişen hastalarda mevcut TNFi tedavisinin kesilmesinin ve sekükinumab (anti-IL-17A) veya diğer TNFi tedavilere geçilmesinin uygun olacağını düşünmekteyiz.
Tumor necrosis factor inhibitor (TNFi) therapies are currently one of the most important treatment options in rheumatic diseases. However, the use of these agents has been shown to be associated with the development of paradoxical autoimmune reactions. In this case report, we aimed to discuss the patient who developed paradoxical sarcoidosis under etanercept treatment in the light of current literature. Mediastinal lymphadenopathy and central located nodules in both lungs were detected in the 40-year-old male patient who had been using etanercept (50 mg/week subcutaneously) for 3 years with the diagnosis of psoriatic arthritis (PsA). Lymph node biopsy revealed non-caseified granulomatous inflammation. The patient was diagnosed as as asymptomatic paradoxical sarcoidosis and etanercept treatment was stopped. PsA clinical activity scores of patients were increased during the 6th month of follow-up. Therefore, secukinumab, interleukin 17A inhibitor (anti-IL17A), was started. Nearly complete regression of mediastinal lymph nodes was observed in the first year of the patient's follow-up. We think that the discontinuation of TNFi treatment and secukinumab (anti-IL17A) or other TNFi agents can be used safely in patients who develop paradoxical sarcoidosis during TNFi treatments.
Tumor necrosis factor inhibitor (TNFi) therapies are currently one of the most important treatment options in rheumatic diseases. However, the use of these agents has been shown to be associated with the development of paradoxical autoimmune reactions. In this case report, we aimed to discuss the patient who developed paradoxical sarcoidosis under etanercept treatment in the light of current literature. Mediastinal lymphadenopathy and central located nodules in both lungs were detected in the 40-year-old male patient who had been using etanercept (50 mg/week subcutaneously) for 3 years with the diagnosis of psoriatic arthritis (PsA). Lymph node biopsy revealed non-caseified granulomatous inflammation. The patient was diagnosed as asymptomatic paradoxical sarcoidosis and etanercept treatment was stopped. PsA clinical activity scores of patient were increased during the 6th month follow-up. Therefore, secukinumab, interleukin 17A inhibitör (anti-IL17A), was started. Nearly complete regression of mediastinal lymph nodes was observed in the first year follow-up of the patient. We think that the discontinuation of TNFi treatment and secukinumab (anti-IL17A) or other TNFi agents can be used safely in patients who develop paradoxical sarcoidosis during TNFi treatments.
Field : Sağlık Bilimleri
Journal Type : Ulusal
Article Detail 
Similar Articles
Download PDF
Journal Information
Listen Paper
Cite
Print This Page
Share
Mendeley
